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1. Alcohol, medical drugs and driving 
Nowadays, we come across quite different, partly contradictory, statements on 
drug-ethanol interactions in handbooks /1, 3/ , official lists 110/ , reviews /6, 
8/ and the media. 
Until now, only a few reports dealing with medical drug usage in drinking 
drivers are based on empirical field studies (e.g., Garriott et al. /2/ , Möller 
191). 
We may assume that traffic participants who are users of medical drugs continue 
to consume alcoholic beverages as if they were non users /4/. Consequently, 
about 30 percent of drivers who usually take medical drugs continue drinking 
alcohol. Among drivers involved in traffic accidents the number of misusers 
with "mixed consumption" approaches 50 percent. 
The current discussion on which upper limit of blood alcohol concentration 
(BAC) should be provided with driving considers more and more possible 
coergisms (interactions) of medical drugs and alcohol even at low BAC values. 
2. What does "coergism" mean? 
"Coergism" means coaction of drugs from different chemical substances in a 
value-free manner. English terminology of pharmacologists perfers the lernt 
"interaction" which denotes the coaction of different drugs either with beneficial 
or adverse reactions. In clinical pharmacology, "interactions" indicate 
adverse/unwanted side effects more than beneficial responses. Interactions 
(coergisms) may be pharmacokinetic (alteration of the absorption, distribution , 
biotransformation or elimination/excretion of drug by another) as well as 
pharmacodynamic (e.g., interactions between agonists and antagonists at drug 
receptors). In general pharmacology, strongly, the term "coergism" designates 
synergistic or antagonistic changes of intensity due to drug-drug coaction, 
whereas "interactions" include changes of intensity and quality of drug effect 
profiles. 
3. Problems to evaluate studies on drug-ethanol coergisms with 
psychotropic drugs 
Krüger et al. (1990) have selected, analysed and evaluated a large quanlity of 
data · from various studies on drugs and alcohol relative to psychological 
variables. They included studies only fulfilling defined criteria concerning 
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dependent variables of different psychological classes, blood alcohol 
concentration of 0.08 percent and below, drugs and alcohol applied orally. The 
basic criterion of selection was a multivariate standard design used by the 
investigators: placebo vs placebo, ethanol vs placebo, placebo vs drug, ethanol 
vs drug. 
From a psychopharmacological perspective we compared the evaluations of 
Krüger et al. (A) with those .drawn from the drug register "Rote Liste" (B): 
Table 1: Differences of reported drug-ethanol interactions with psychotropic 
drugs. 
Class of drugs Review A 
antidepressants 
neuroleptics 
tranquilizers/anxiolytics 
nootropics 
+10 
0 
+10 
0 
+ synergistic effect by interaction generally 
( +) synergistic effect in single substances 
0 no evidence for interaction 
+10 contradictory observations 
Review B 
(+) 
+ 
+ 
0 
Difficulties to generalize data from different studies may be demonstrated with 
the drug amitriptyline, a frequently prescribed antidepressant. Krüger et al. 
found six studies regarding drug-ethanol coergisms with amitriptyline mostly 
applied as a standard drug within a single dose regimen: 50 mg (3), 25 mg (2) , 
75 mg (1).0nly women were included: 3 studies, only men: 2 studies, both: 1 
study. Pretreatment time with ethanol: 60 min (4), 180 min (1), 0 min (1). BAC 
values (%) at beginning the test programme: 0.076 (3), 0.067 (1), 0.063 (1), 
0.084 (1). Two studies with a repeated dose regimen were identified. 
Amitriptyline dosage used: 75 mg or 30 mg daily. Time of ethanol intake was 
equal to the time of drug application for testing psychological variables. 
Among antidepressants /7, 11/, amitriptyline belongs to those effecting sedation 
and psychomotor inhibition. Pharmacokinetically, it differs from other 
antidepressants, especially because of a long-acting active metabolite. 
Therefore, amitriptyline seems to be rather unsuitable for acute studies with a 
single dose regimen. Together with alcohol (single dose), effects are determined 
on a very instable level from a pharmacodynamic and pharmacokinetic 
viewpoint. Generally peak concentration levels of drugs should be maintained 
for long time measurements. Unfortunately, none of the reported studies using 
amitriptyline based on steady state conditions. 
736 
Table 2: Antidepressants according to Schönhöfer and Schwabe / 11/. 
Drug name tl/2 daily dose active metabolite 
(hours) (mg) 
Amitriptyline 17 - 40 50 - 150 nortriptyline 
Clomipramine 18 - 24 50 - 150 
Desipramine 13 - 23 50 - 150 
Imipramine 10 - 16 50 - 150 desipramine 
Nortriptyline 18 - 44 30 - 125 
Doxepine 11 - 23 50 - 150 desmethyldoxepine 
(tl/2:33-80hs) 
Fluoxetine 48 - 96 100 - 300 norfluoxetine 
(tl/2: 7 days) 
Paroxetine 24 20- 50 
Trazodone 7 - 8 75 - 300 
Sulpiride 7 - 9 150 - 300 
Similarly, neuroleptics, tranquilizers/anxiolytics are nonhomogenuos classes of 
drugs because of their quite different pharmacodynamics and pharmacokinetics 
151. lt should be mentioned that alcohol may inhibit drug metabolizing systems 
after intake acutely in non-users. Alcohol abusers may develop a metabolic 
tolerance by increasing the drug biotransformation /5, 8/ . With antidepressants 
we must distinguish between drugs stimulating or depressing psychomotor 
behavior. Furthermore with some neuroleptics, we can find that smaller doses 
may produce increasing and higher doses depressing activity in patients. 
Moreover, in the special case of sulpiride a lower dose may be classified as an 
activating antidepressant, a higher dose as a depressant neuroleptic. 
4. Clinical studies 
The majority of drugs investigated in drug-ethanol interaction studies are used 
by patients (prescribed or self-medicated). Therefore, clinical studies should be 
promoted to allow a better evalution of the hazardous aspects with combined 
ethanol-drug intake (see /13/ ). Modelling the actual behavior of patients as 
traffic participants for drug-interaction studies is needed (see also /12/ ). In 
contrast to healthy probands, clinical studies on drug-ethanol coergisms in 
patients are rare and connected with ethical problems. Therefore, information on 
drug-ethanol interactions will remain preliminary. 
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